FDA has granted Fast Track designation to selinexor, Karyopharm Therapeutics Inc.’s first in class, oral SINE compound, for the treatment of patients with diffuse large B-cell lymphoma who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
